Tony Muslin is currently Vice President, Head of the Cardiovascular and Fibrosis Therapeutic Strategic Unit at Sanofi Global R&D. He is based in Cambridge, Massachusetts, USA, and Chilly-Mazarin, France. He is in charge of developing new drug discovery programs in the following therapeutic areas: hyperlipidemia, heart failure, cardiomyopathy, and pulmonary and renal fibrosis. His group advances drug discovery programs from inception through clinical development. He is also involved in identifying and managing external partnerships with biotechnology companies and academic groups.

Previously, Tony was the Head of Research in Cardiovascular and Metabolic Diseases (CVM) at Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. He was responsible for developing drug discovery programs to help treat atherosclerosis, heart failure, hyperlipidemia, diabetes and obesity.

Prior to working in the pharma industry, Tony was the Oliver M. Langenberg Distinguished Professor of the Science and Practice of Medicine and Director of the Center for Cardiovascular Research at Washington University School of Medicine in Saint Louis, Missouri, USA. His lab was focused on the role of signal transduction cascades in the development of heart failure. He trained at Yale University, Harvard Medical School and the University of California, San Francisco.